OS Therapies (NYSEAMERICAN:OSTX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of OS Therapies (NYSEAMERICAN:OSTX) in a research report report published on Friday morning,Benzinga reports. D. Boral Capital currently has a $20.00 price target on the stock.

OS Therapies Stock Up 2.9%

NYSEAMERICAN OSTX opened at $1.41 on Friday. The firm has a 50-day moving average price of $1.40 and a two-hundred day moving average price of $1.68. OS Therapies has a 12-month low of $1.12 and a 12-month high of $2.57. The company has a market capitalization of $49.65 million, a P/E ratio of -1.72 and a beta of -3.80.

Hedge Funds Weigh In On OS Therapies

A number of hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP bought a new position in shares of OS Therapies in the third quarter worth $29,000. Mercer Global Advisors Inc. ADV acquired a new stake in OS Therapies during the third quarter worth about $40,000. Ground Swell Capital LLC bought a new position in OS Therapies in the 3rd quarter valued at about $40,000. Bridgeway Capital Management LLC bought a new position in OS Therapies in the 2nd quarter valued at about $47,000. Finally, Jane Street Group LLC acquired a new position in shares of OS Therapies in the 4th quarter valued at approximately $39,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.